Clinical Trial Update: Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating digital-PCR analysis during interrupted imatinib therapy in PCR-negative chronic myeloid leukemia patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Imatinib (imatinib)

Snippet

Sponsor: University of Milano Bicocca | Conditions: Chronic Myeloid Leukemia | Phase 4 | Status: COMPLETED